These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34034278)

  • 41. Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients.
    Iborra M; García-Morales N; Rubio S; Bertoletti F; Calvo M; Taxonera C; Boscá-Watts MM; Sierra M; Mancenido N; Beltrán B; Nantes Castillejo Ó; García-Planella E; Vera I; Alba C; Martí-Aguado D; Ballester MP; Cano-Sanz N; Pajares-Villarroya R; Cerrillo E; Cañada A; Nos P
    Sci Rep; 2020 Oct; 10(1):17774. PubMed ID: 33082359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical efficacy and safety of golimumab in biologically experienced and naive patients with active ulcerative colitis: A real-life experience from two Italian IBD centers.
    Orlandini B; Dragoni G; Variola A; Massella A; Bagnoli S; Campi R; Rogai F
    J Dig Dis; 2018 Aug; 19(8):468-474. PubMed ID: 30039533
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
    Colombel JF; Sandborn WJ; Ghosh S; Wolf DC; Panaccione R; Feagan B; Reinisch W; Robinson AM; Lazar A; Kron M; Huang B; Skup M; Thakkar RB
    Am J Gastroenterol; 2014 Nov; 109(11):1771-80. PubMed ID: 25155227
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial.
    Schreiber S; Feagan BG; Peyrin-Biroulet L; Vermeire S; Faes M; Harris K; Oortwijn A; Daniele P; Patel H; Danese S
    J Crohns Colitis; 2023 Jun; 17(6):863-875. PubMed ID: 36756874
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.
    Reinisch W; Gibson PR; Sandborn WJ; Feagan BG; Strauss R; Johanns J; Padgett L; Adedokun OJ; Colombel JF; Collins J; Rutgeerts P; Tarabar D; Marano C
    J Crohns Colitis; 2018 Aug; 12(9):1053-1066. PubMed ID: 29917070
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.
    Paschos P; Katsoula A; Salanti G; Giouleme O; Athanasiadou E; Tsapas A
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1174-1185. PubMed ID: 30378141
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Etrolizumab for induction of remission in ulcerative colitis.
    Rosenfeld G; Parker CE; MacDonald JK; Bressler B
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouch-Anal Anastomosis, Ileostomy and Anti-TNFα Therapy.
    van der Valk ME; Mangen MJ; Severs M; van der Have M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; van de Meeberg PC; Mahmmod N; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk C; Vermeijden JR; Siersema PD; Leenders M; Oldenburg B; ;
    J Crohns Colitis; 2015 Nov; 9(11):1016-23. PubMed ID: 26254056
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis.
    Xu Y; Adedokun OJ; Chan D; Hu C; Xu Z; Strauss RS; Hyams JS; Turner D; Zhou H
    J Clin Pharmacol; 2019 Apr; 59(4):590-604. PubMed ID: 30536638
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study.
    Willian MK; D'Haens G; Yarlas A; Joshi AV
    J Patient Rep Outcomes; 2018 Dec; 2():22. PubMed ID: 30294708
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.
    Dreesen E; Kantasiripitak W; Detrez I; Stefanović S; Vermeire S; Ferrante M; Bouillon T; Drobne D; Gils A
    Inflamm Bowel Dis; 2020 Mar; 26(4):570-580. PubMed ID: 31372650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prospective cohort study of appendicectomy for treatment of therapy-refractory ulcerative colitis.
    Stellingwerf ME; Sahami S; Winter DC; Martin ST; D'Haens GR; Cullen G; Doherty GA; Mulcahy H; Bemelman WA; Buskens CJ
    Br J Surg; 2019 Nov; 106(12):1697-1704. PubMed ID: 31393608
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Health-related quality of life in Chinese patients with mild and moderately active ulcerative colitis.
    Zheng K; Zhang S; Wang C; Zhao W; Shen H
    PLoS One; 2015; 10(4):e0124211. PubMed ID: 25915777
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study.
    Berends SE; Strik AS; Jansen JM; de Boer NK; van Egmond PS; Brandse JF; Mathôt RA; D'Haens GR; Löwenberg M
    Scand J Gastroenterol; 2019 Jun; 54(6):700-706. PubMed ID: 31132014
    [No Abstract]   [Full Text] [Related]  

  • 56. Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study.
    Yarlas A; D'Haens G; Willian MK; Teynor M
    Inflamm Bowel Dis; 2018 Jan; 24(2):450-463. PubMed ID: 29361097
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open.
    Biedermann L; Dubinsky MC; Vermeire S; Fellmann M; Gardiner S; Hur P; Mundayat R; Panés J; Rubin DT
    Inflamm Bowel Dis; 2023 Sep; 29(9):1370-1379. PubMed ID: 36242764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.
    Dubinsky MC; Jairath V; Feagan BG; Naegeli AN; Tuttle J; Morris N; Shan M; Arora V; Lissoos T; Agada N; Hibi T; Sands BE
    BMJ Open Gastroenterol; 2023 Mar; 10(1):. PubMed ID: 37001911
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil.
    Sassaki LY; Miszputen SJ; Kaiser Junior RL; Catapani WR; Bafutto M; Scotton AS; Zaltman C; Baima JP; Ramos HS; Faria MAG; Gonçalves CD; Guimaraes IM; Flores C; Amarante HMBS; Nones RB; Parente JML; Lima MM; Chebli JM; Ferrari MLA; Campos JF; Sanna MGP; Ramos O; Parra RS; da Rocha JJR; Feres O; Feitosa MR; Caratin RF; Senra JT; Santana GO
    World J Gastroenterol; 2021 Jun; 27(23):3396-3412. PubMed ID: 34163120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validation of the inflammatory bowel disease questionnaire in Swedish patients with ulcerative colitis.
    Hjortswang H; Järnerot G; Curman B; Sandberg-Gertzén H; Tysk C; Blomberg B; Almer S; Ström M
    Scand J Gastroenterol; 2001 Jan; 36(1):77-85. PubMed ID: 11218243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.